HUP0203162A3 - Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer - Google Patents

Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Info

Publication number
HUP0203162A3
HUP0203162A3 HU0203162A HUP0203162A HUP0203162A3 HU P0203162 A3 HUP0203162 A3 HU P0203162A3 HU 0203162 A HU0203162 A HU 0203162A HU P0203162 A HUP0203162 A HU P0203162A HU P0203162 A3 HUP0203162 A3 HU P0203162A3
Authority
HU
Hungary
Prior art keywords
nsaid
inhibition
treatment
colorectal cancer
kinase inhibitor
Prior art date
Application number
HU0203162A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Wyeth Holdings Corp Madison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corp Madison filed Critical Wyeth Holdings Corp Madison
Publication of HUP0203162A2 publication Critical patent/HUP0203162A2/hu
Publication of HUP0203162A3 publication Critical patent/HUP0203162A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0203162A 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer HUP0203162A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (2)

Publication Number Publication Date
HUP0203162A2 HUP0203162A2 (hu) 2003-01-28
HUP0203162A3 true HUP0203162A3 (en) 2006-07-28

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203162A HUP0203162A3 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Country Status (24)

Country Link
EP (1) EP1202746B1 (https=)
JP (1) JP2003507342A (https=)
KR (1) KR20020018201A (https=)
CN (1) CN1229142C (https=)
AR (1) AR029763A1 (https=)
AT (1) ATE341341T1 (https=)
AU (1) AU783116B2 (https=)
BR (1) BR0013219A (https=)
CA (1) CA2380904C (https=)
CZ (1) CZ2002474A3 (https=)
DE (1) DE60031127T2 (https=)
DK (1) DK1202746T3 (https=)
EA (1) EA006876B1 (https=)
ES (1) ES2272305T3 (https=)
HK (1) HK1042244A1 (https=)
HU (1) HUP0203162A3 (https=)
IL (1) IL147913A0 (https=)
MX (1) MXPA02001448A (https=)
NO (1) NO20020663L (https=)
NZ (1) NZ517120A (https=)
PL (1) PL353267A1 (https=)
PT (1) PT1202746E (https=)
WO (1) WO2001012227A1 (https=)
ZA (1) ZA200201156B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
CN1190197C (zh) * 2000-03-13 2005-02-23 惠氏控股公司 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
WO2003008409A1 (en) 2001-07-16 2003-01-30 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2837227C (en) * 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135900A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
BR9814116A (pt) * 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico

Also Published As

Publication number Publication date
DE60031127T2 (de) 2007-02-01
EP1202746A1 (en) 2002-05-08
DE60031127D1 (de) 2006-11-16
EA200200246A1 (ru) 2002-08-29
MXPA02001448A (es) 2002-07-02
HK1042244A1 (zh) 2002-08-09
AR029763A1 (es) 2003-07-16
HUP0203162A2 (hu) 2003-01-28
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
BR0013219A (pt) 2002-04-23
KR20020018201A (ko) 2002-03-07
EP1202746B1 (en) 2006-10-04
NO20020663D0 (no) 2002-02-11
ZA200201156B (en) 2003-05-12
CA2380904C (en) 2009-02-10
DK1202746T3 (da) 2007-01-02
JP2003507342A (ja) 2003-02-25
EA006876B1 (ru) 2006-04-28
PL353267A1 (en) 2003-11-03
CN1370080A (zh) 2002-09-18
IL147913A0 (en) 2002-08-14
PT1202746E (pt) 2007-01-31
ATE341341T1 (de) 2006-10-15
ES2272305T3 (es) 2007-05-01
WO2001012227A1 (en) 2001-02-22
AU6395900A (en) 2001-03-13
NO20020663L (no) 2002-04-09
NZ517120A (en) 2004-10-29
CZ2002474A3 (cs) 2003-02-12
CN1229142C (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
IL147913A0 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
PL340800A1 (en) Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
IL151249A0 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
HUP0301269A3 (en) Phthalazinone derivatives and pharmaceutical compositions containing them
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
NO985652D0 (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
HUP0003194A3 (en) Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
IL152846A0 (en) Pyridazinone derivatives and pharmaceutical compositions containing the same
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
HUP0303998A3 (en) Phthalazinones derivatives and pharmaceutical compositions containing them
AU2002367172A1 (en) 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
HUP0200088A3 (en) Pyridazin-3-one derivatives and pharmaceutical compositions containing the same
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
AU2002353147A8 (en) 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
AU2026801A (en) Melanin synthesis inhibition compound and composition containing the same
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA
IL154354A0 (en) Composition for prophylaxis and treatment of cancer
AU5706500A (en) Medicinal compositions for treating colorectal cancer
SI1263503T1 (sl) Uporaba cianokinolinov za zdravljenje ali inhibiranje polipov na crevesju

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished